DGAP-News: CO.DON AG: major shareholder gives strong commitment to regenerative cell therapies

CO.DON AG - major shareholder gives strong commitment to regenerative cell therapies

Berlin / Teltow, 17.10.2018 - Bauerfeind Group, the largest shareholder in CO.DON AG, has acquired roughly 26% of the shares in Xintela AG, based in Lund, Sweden.

CO.DON AG reported on 9 July that a letter of intent had been signed with Xintela. The aim is the joint development of a stem cell product to treat cartilage diseases, including osteoarthritis, on the European and North American markets.

In this case, Xintela would contribute their marker and stem cell technology, as well as GMP production capacities. CO.DON will provide financial resources and competencies in clinical development and marketing.

Professor Bauerfeind, CEO of Bauerfeind Group: "CO.DON AG has already shown that it can successfully bring a new product from development to marketing authorisation through to market. Now the aim is to take the next step and develop further innovative therapeutic methods. In partnership with Xintela there is now an opportunity to work towards developing a sustainable and causal treatment for osteoarthritis, one of the most widespread ailments of our time. I support this endeavour wholeheartedly."

Ralf Jakobs, CEO of CO.DON AG: "We are very pleased with the dedication of our largest shareholder. The investment made by the Bauerfeind Group now places the intended cooperation with Xintela on a broader basis of conceivable possibilities. With the expansion and further development of our product pipeline, we intend to continue to play a leading role in the development of pioneering technologies in the field of regenerative medicine and to live up to our claim of being "human cell experts".

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 we received marketing authorisation for the advanced therapy medicinal product Spherox from the European Medicines Agency. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de